Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.82 USD | +0.33% | +0.30% | +2.49% |
May. 23 | Taro Pharmaceutical's Shareholders Approve Merger With Sun Pharmaceutical | MT |
May. 22 | Transcript : Taro Pharmaceutical Industries Ltd. - Shareholder/Analyst Call |
Financials (USD)
Sales 2024 | 629M | Sales 2025 * | - | Capitalization | 1.61B |
---|---|---|---|---|---|
Net income 2024 | 53M | Net income 2025 * | - | EV / Sales 2024 | 2.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 |
29.6
x | P/E ratio 2025 * |
-
| Employees | 1,554 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 17.92% |
Latest transcript on Taro Pharmaceutical Industries Ltd.
1 day | +0.33% | ||
1 week | +0.30% | ||
1 month | +1.01% | ||
3 months | +1.71% | ||
6 months | +16.04% | ||
Current year | +2.49% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 16-11-30 | |
William Coote
DFI | Director of Finance/CFO | 69 | 07-12-31 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Stein
BRD | Director/Board Member | 73 | 20-01-31 |
Chairman | 68 | 10-09-21 | |
Director/Board Member | 67 | 10-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 7 M€ | +5.36% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 42.82 | +0.33% | 43,868 |
24-05-30 | 42.68 | +0.57% | 15,220 |
24-05-29 | 42.44 | -0.59% | 65,199 |
24-05-28 | 42.69 | -.--% | 54,908 |
24-05-24 | 42.69 | -0.14% | 45,929 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+2.49% | 1.61B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- TARO Stock